Sandu Pharmaceuticals Completes Leadership Transitions; Names New Managing Director and Board Appointments

Sandu Pharmaceuticals Completes Leadership Transitions; Names New Managing Director and Board Appointments​

Sandu Pharmaceuticals Ltd has undergone significant changes in its senior management and board composition following a recent board meeting held on July 11, 2026. The company took several actions relating to the loss of a director, appointments, and structural revisions across key committees.

The Board of Directors formally noted the demise of Shri Umesh B. Sandu (DIN: 01132141), who served as Managing Director, having passed away on June 19, 2026. The board expressed sincere appreciation for his contribution and leadership during his tenure.

Key Appointments and Redesignations​

The Board approved the appointment of Dr. Neeti Madan Kapre (DIN: 06801264) as an Additional Non-Executive Independent Director. This appointment is set for a first term of five consecutive years, effective from July 11, 2026, until July 10, 2031.

Dr. Kapre’s profile includes qualifications such as MBBS and MS (ENT).

Concurrently, Shri Balram Viswanathan (DIN: 10245195) was redesigned from Chairman and Non-Executive Independent Director to Chairman and Managing Director of Sandu Pharmaceuticals Ltd and Key Managerial Personnel. This role is effective for a term of three years, commencing on July 11, 2026, and running up to July 10, 2029. Mr. Viswanathan holds qualifications including B.Com., FCA, and CPA (USA), bringing over 30 years of experience in the financial services industry across various areas such as Audit and Mergers & Acquisitions Advisory.

Board Committee Reconstitution​

In response to changes in leadership, the Board approved the immediate reconstitution of three critical committees: the Audit Committee, the Nomination and Remuneration Committee, and the Stakeholders' Relationship Committee.

The revised compositions are detailed below:

Audit Committee Composition

Nomination and Remuneration Committee Composition

Stakeholders' Relationship Committee Composition

Policy and Governance Updates​

The Board also approved the revision of the Company's Vigil Mechanism Policy. This revision involved updating the policy to replace the late Shri Umesh B. Sandu with Shri Balram Viswanathan in his capacity as Chairman and Managing Director, wherever applicable within the document.

The company detailed the structure of its whistle blower mechanism, which includes establishing a Nodal Officer (Mr Balram Viswanathan) to receive protected disclosures. The policy mandates that all protected disclosures must be submitted in writing and securedly envelope marked.

A table outlining key management personnel for governance oversight was provided:

Stock Price Movement​

Sandu Pharmaceuticals Ltd settled at ₹41.00 on Friday, ticking up by 1.06%. The shares traded within an intraday range spanning from a low of ₹40.67 to a high of ₹41.47.